Research ExplorerPublicationsEfficacy of the protease inhibitor BI 201335, polymerase inh...

Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection.

Standard

Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. / Zeuzem, Stefan; Asselah, Tarik; Angus, Peter; Zarski, Jean-Pierre; Larrey, Dominique; Müllhaupt, Beat; Gane, Ed; Schuchmann, Marcus; Lohse, Ansgar W.; Pol, Stanislas; Bronowicki, Jean-Pierre; Roberts, Stuart; Arasteh, Keikawus; Zoulim, Fabien; Heim, Markus; Stern, Jerry O; Kukolj, George; Nehmiz, Gerhard; Haefner, Carla; Boecher, Wulf Otto.

In: GASTROENTEROLOGY, Vol. 141, No. 6, 6, 2011, p. 2014-2047.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Zeuzem, S, Asselah, T, Angus, P, Zarski, J-P, Larrey, D, Müllhaupt, B, Gane, E, Schuchmann, M, Lohse, AW, Pol, S, Bronowicki, J-P, Roberts, S, Arasteh, K, Zoulim, F, Heim, M, Stern, JO, Kukolj, G, Nehmiz, G, Haefner, C & Boecher, WO 2011, 'Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection.', GASTROENTEROLOGY, vol. 141, no. 6, 6, pp. 2014-2047. <http://www.ncbi.nlm.nih.gov/pubmed/21925126?dopt=Citation>

APA

Zeuzem, S., Asselah, T., Angus, P., Zarski, J-P., Larrey, D., Müllhaupt, B., Gane, E., Schuchmann, M., Lohse, A. W., Pol, S., Bronowicki, J-P., Roberts, S., Arasteh, K., Zoulim, F., Heim, M., Stern, J. O., Kukolj, G., Nehmiz, G., Haefner, C., & Boecher, W. O. (2011). Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. GASTROENTEROLOGY, 141(6), 2014-2047. [6]. http://www.ncbi.nlm.nih.gov/pubmed/21925126?dopt=Citation

Vancouver

Zeuzem S, Asselah T, Angus P, Zarski J-P, Larrey D, Müllhaupt B et al. Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. GASTROENTEROLOGY. 2011;141(6):2014-2047. 6.

Bibtex

@article{20ea0ffd49e64deeb3f639cf41ffb567,
title = "Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection.",
abstract = "Therapeutic regimens are being developed for patients with hepatitis C virus (HCV) infection that do not include the combination of peginterferon alfa and ribavirin. We investigated the antiviral effect and safety of BI 201335 (an inhibitor of the NS3/4A protease) and BI 207127 (an inhibitor of the NS5B non-nucleoside polymerase) with ribavirin.",
keywords = "Humans, Male, Female, Middle Aged, Treatment Outcome, Genotype, Viral Load, Drug Therapy, Combination, Hepatitis C, Chronic/*drug therapy/virology, Antiviral Agents/adverse effects/*therapeutic use, Hepacivirus/*drug effects/genetics, Oligopeptides/adverse effects/*therapeutic use, Protease Inhibitors/adverse effects/therapeutic use, RNA Replicase/*antagonists & inhibitors, RNA, Viral/analysis/blood/drug effects, Ribavirin/adverse effects/*therapeutic use, Thiazoles/adverse effects/*therapeutic use, Viral Nonstructural Proteins/antagonists & inhibitors, Humans, Male, Female, Middle Aged, Treatment Outcome, Genotype, Viral Load, Drug Therapy, Combination, Hepatitis C, Chronic/*drug therapy/virology, Antiviral Agents/adverse effects/*therapeutic use, Hepacivirus/*drug effects/genetics, Oligopeptides/adverse effects/*therapeutic use, Protease Inhibitors/adverse effects/therapeutic use, RNA Replicase/*antagonists & inhibitors, RNA, Viral/analysis/blood/drug effects, Ribavirin/adverse effects/*therapeutic use, Thiazoles/adverse effects/*therapeutic use, Viral Nonstructural Proteins/antagonists & inhibitors",
author = "Stefan Zeuzem and Tarik Asselah and Peter Angus and Jean-Pierre Zarski and Dominique Larrey and Beat M{\"u}llhaupt and Ed Gane and Marcus Schuchmann and Lohse, {Ansgar W.} and Stanislas Pol and Jean-Pierre Bronowicki and Stuart Roberts and Keikawus Arasteh and Fabien Zoulim and Markus Heim and Stern, {Jerry O} and George Kukolj and Gerhard Nehmiz and Carla Haefner and Boecher, {Wulf Otto}",
year = "2011",
language = "English",
volume = "141",
pages = "2014--2047",
journal = "GASTROENTEROLOGY",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "6",

}

RIS

TY - JOUR

T1 - Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection.

AU - Zeuzem, Stefan

AU - Asselah, Tarik

AU - Angus, Peter

AU - Zarski, Jean-Pierre

AU - Larrey, Dominique

AU - Müllhaupt, Beat

AU - Gane, Ed

AU - Schuchmann, Marcus

AU - Lohse, Ansgar W.

AU - Pol, Stanislas

AU - Bronowicki, Jean-Pierre

AU - Roberts, Stuart

AU - Arasteh, Keikawus

AU - Zoulim, Fabien

AU - Heim, Markus

AU - Stern, Jerry O

AU - Kukolj, George

AU - Nehmiz, Gerhard

AU - Haefner, Carla

AU - Boecher, Wulf Otto

PY - 2011

Y1 - 2011

N2 - Therapeutic regimens are being developed for patients with hepatitis C virus (HCV) infection that do not include the combination of peginterferon alfa and ribavirin. We investigated the antiviral effect and safety of BI 201335 (an inhibitor of the NS3/4A protease) and BI 207127 (an inhibitor of the NS5B non-nucleoside polymerase) with ribavirin.

AB - Therapeutic regimens are being developed for patients with hepatitis C virus (HCV) infection that do not include the combination of peginterferon alfa and ribavirin. We investigated the antiviral effect and safety of BI 201335 (an inhibitor of the NS3/4A protease) and BI 207127 (an inhibitor of the NS5B non-nucleoside polymerase) with ribavirin.

KW - Humans

KW - Male

KW - Female

KW - Middle Aged

KW - Treatment Outcome

KW - Genotype

KW - Viral Load

KW - Drug Therapy, Combination

KW - Hepatitis C, Chronic/drug therapy/virology

KW - Antiviral Agents/adverse effects/therapeutic use

KW - Hepacivirus/drug effects/genetics

KW - Oligopeptides/adverse effects/therapeutic use

KW - Protease Inhibitors/adverse effects/therapeutic use

KW - RNA Replicase/antagonists & inhibitors

KW - RNA, Viral/analysis/blood/drug effects

KW - Ribavirin/adverse effects/therapeutic use

KW - Thiazoles/adverse effects/therapeutic use

KW - Viral Nonstructural Proteins/antagonists & inhibitors

KW - Humans

KW - Male

KW - Female

KW - Middle Aged

KW - Treatment Outcome

KW - Genotype

KW - Viral Load

KW - Drug Therapy, Combination

KW - Hepatitis C, Chronic/drug therapy/virology

KW - Antiviral Agents/adverse effects/therapeutic use

KW - Hepacivirus/drug effects/genetics

KW - Oligopeptides/adverse effects/therapeutic use

KW - Protease Inhibitors/adverse effects/therapeutic use

KW - RNA Replicase/antagonists & inhibitors

KW - RNA, Viral/analysis/blood/drug effects

KW - Ribavirin/adverse effects/therapeutic use

KW - Thiazoles/adverse effects/therapeutic use

KW - Viral Nonstructural Proteins/antagonists & inhibitors

M3 - SCORING: Journal article

VL - 141

SP - 2014

EP - 2047

JO - GASTROENTEROLOGY

JF - GASTROENTEROLOGY

SN - 0016-5085

IS - 6

M1 - 6

ER -